Literature DB >> 10411478

Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.

J Benes1, A Parada, A A Figueiredo, P C Alves, A P Freitas, D A Learmonth, R A Cunha, J Garrett, P Soares-da-Silva.   

Abstract

A series of esters of the major metabolite of oxcarbazepine (2), 10, 11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, were synthesized and evaluated for their anticonvulsant and brain sodium channel-blocking properties. The compounds were assayed intraperitoneally and per os in rats against seizures induced by maximal electroshock (MES). Neurologic deficit was evaluated by the rotarod test. The enantiomeric acetates (R)-11 and (S)-12 were the most active of the series against MES-induced seizures with oral ED(50) values at t(max) of 10.9 +/- 2.3 and 4.7 +/- 0.9 mg/kg, respectively. After intraperitoneal administration, carbamazepine (1) behaved more potently than 2 and all other new dibenz[b, f]azepine-5-carboxamide derivatives in the MES test; compounds 2 and 12 were equally potent. In the rotarod test, low doses of 1 produced considerable motor impairment, which did not occur with 2, enantiomeric alcohols (S)-6, (R)-7, and racemic alcohol 8, or racemic acetate 10 or (R)-11. The potencies of the racemic and enantiomerically pure alcohols 8, (S)-6, and (R)-7 derived from 2 in the MES and rotarod test were found to be similar between them, and consequently they exhibit similar protective index values. All three forms of the alcohol and their corresponding acetates (pairs 8 & 10, 6 & 12, and 7 & 11) were found to differ in the MES or rotarod tests; the ED(50) value for (S)-6 against MES-induced seizures was nearly 3-fold that for (S)-12. The protective index also differed markedly between all stereoisomers of the alcohol and their corresponding acetates, most pronouncedly for compound (S)-12 which attained the highest value (12.5) among all compounds tested. Blockade of voltage-sensitive sodium channels was studied by investigating [(3)H]batrachotoxinin A 20-alpha-benzoate ([(3)H]BTX) binding. Acetates (R)-11 and (S)-12 were more potent than the standards 1 and 2 at inhibiting the binding of [(3)H]BTX to sodium channels and the influx of (22)Na(+) into rat brain synaptosomes. It is concluded that acetates (R)-11 and (S)-12 are not simple metabolic precursors of alcohols (R)-7 and (S)-6 in rodents but that they possess anticonvulsant and sodium channel-blocking properties in their own right.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411478     DOI: 10.1021/jm980627g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

Review 1.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

Review 2.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

Review 3.  Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.

Authors:  Matt Shirley; Sohita Dhillon
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

4.  Eslicarbazepine acetate: a well-kept secret?

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2010-01       Impact factor: 7.500

5.  [Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate].

Authors:  B J Steinhoff; E Trinka; A S Wendling
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

Review 6.  Eslicarbazepine acetate (BIA 2-093).

Authors:  Luis Almeida; Patrício Soares-da-Silva
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 7.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

Review 8.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

9.  Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment.

Authors:  Luis Almeida; J Hendrick Potgieter; Joana Maia; M Alida Potgieter; Fernando Mota; P Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2007-12-21       Impact factor: 2.953

10.  Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures.

Authors:  Martin E Brown; Rif S El-Mallakh
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.